Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Dr. Fariborze B. Barhamand

Hematology Oncology | Hematology | Oncology
100 Spalding Dr, Ste 110, 
Naperville, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
100 Spalding Dr, Ste 110, 
Naperville, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Fariborze Barhamand is a Hematologist Oncology specialist and a Hematologist in Naperville, Illinois. Dr. Barhamand is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

100 Spalding Dr, Ste 110, Naperville, IL 60540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 10 Less Clinical Trials

1 Total Publications

Management of pharyngolaryngeal dysesthesia associated with oxaliplatin therapy.
Management of pharyngolaryngeal dysesthesia associated with oxaliplatin therapy.
Journal: Clinical journal of oncology nursing
Published: August 22, 2003
Similar Doctors
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Agne Paner
Hematology Oncology | Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Agne Paner
Hematology Oncology | Hematology | Oncology
2160 S 1st Ave, 
Maywood, IL 
 (17.7 miles away)
708-327-2206
Languages Spoken:
English
See accepted insurances

Agne Paner is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Paner is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Smoldering Multiple Myeloma, and Bone Marrow Aspiration.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Regina M. Stein
Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Regina M. Stein
Hematology | Oncology
676 N St Clair St Ste 2140, Arkes Pavilion, 
Chicago, IL 
 (29.2 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Regina Stein is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Stein has been practicing medicine for over 24 years and is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Breast Cancer.

Robert A. Bayer
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert A. Bayer
Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert A. Bayer
Hematology | Oncology
10 Health Service Dr, 
Dekalb, IL 
 (32.4 miles away)
815-756-5255
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Bayer is a Hematologist and an Oncologist in Dekalb, Illinois. Dr. Bayer is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Lynch Syndrome, and Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barhamand's expertise for a condition
ConditionClose
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile